The administration of rapamycin or other mTOR inhibitors was shown to delay cancer formation in cancer-prone mice infected by the Human Papilloma Virus (HPV) [80] or carrying mutations in Her2/Neu [81, 82], p53 [83, 84], PTEN [85], and other types of mutations [86, 87]. This evidence concerns the gene ERBB2 and cancer.